PsychonautWiki Archive

MiPLA: Difference between revisions

← Older edit
>RoRoKey
m reverted last change because i didnt know what i was doing
>Graham
wiki ref formatting
 
(36 intermediate revisions by 7 users not shown)
Line 1: Line 1:
{{SummarySheet}}
{{SubstanceBox/MiPLA}}
'''N-Methyl-N-isopropyllysergamide''' (also known as '''methylisopropyllysergamide''', '''Lamide''' and '''MiPLA''') is a lesser-known novel [[psychoactive class::psychedelic]] substance of the [[chemical class::lysergamide]] class. MiPLA is structurally related to [[LSD]] and likely has a similar mechanism of action, working primarily by binding to the [[serotonin]]-2A [[receptor]] in the brain.{{citation needed}}


'''N-Methyl-N-isopropyllysergamide''' (also known as '''methylisopropyllysergamide''', '''Lamide''' and '''MiPLA''') is a novel [[psychoactive class::psychedelic]] substance of the [[chemical class::lysergamide]] class. MiPLA is chemically similar to LSD and has a similar mechanism of action, working primarily by stimulating [[serotonin]] [[receptors]] in the brain.
MiPLA was first discovered by Albert Hoffman as a part of the original structure-activity research for [[LSD]].{{citation needed}} It has recently been researched in greater detail by by a team led by David E. Nichols at Purdue University.{{citation needed}} MiPLA and its effects are also mentioned in Alexander Shulgin's "Pharmacology Notes #9" and "Pharmacology Notes C".<ref>{{cite book|author=Alexander Shulgin|author-link=Alexander Shulgin|title=Pharmacology Notes IX (The Shulgin Lab Books)|publisher=Erowid|url=https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebook9_searchable.pdf}}</ref><ref>{{cite book|author=Alexander Shulgin|author-link=Alexander Shulgin|title=Pharmacology Notes C (The Shulgin Lab Books)|publisher=Erowid|url=https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebookc_searchable.pdf}}</ref> According to Shulgin, human subjects administered MiPLA at doses of 180–300 μg experienced LSD-like psychedelic effects, making it about two- to threefold less potent than LSD.<ref>{{cite journal|last1=Halberstadt|first1=A. L.|last2=Klein|first2=L. M.|last3=Chatha|first3=M.|last4=Valenzuela|first4=L. B.|last5=Stratford|first5=A.|last6=Wallach|first6=Jason|last7=Nichols|first7=D. E.|author-link7=David E. Nichols|last8=Brandt|first8=S. D.|title=Pharmacological characterization of the LSD analog ''N''-ethyl-''N''-cyclopropyl lysergamide (ECPLA)|journal=Psychopharmacology|year=2018|volume=236|pages=799–808|doi=10.1007/s00213-018-5055-9|issn=0033-3158|eissn=1432-2072|oclc=2409222}}</ref>


MiPLA was first discovered by Albert Hoffman as a part of the original structure-activity research for [[LSD]]. It has recently been researched in greater detail by by a team led by David E. Nichols at Purdue University. MiPLA and its effects are also mentioned in Alexander Shulgin's "Pharmacology Notes #9" and "Pharmacology Notes C".<ref>https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebook9_searchable.pdf</ref><ref>https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebookc_searchable.pdf</ref> According to Shulgin, human subjects administered MIPLA at doses of 180–300μg experienced LSD-like psychedelic effects, making it about two- to threefold less potent than LSD.<ref>Halberstadt, A.L., Klein, L.M., Chatha, M. et al. Psychopharmacology (2018). http://dx.doi.org/10.1007/s00213-018-5055-9</ref>
User reports describe the effects of MiPLA as similar to those of LSD but with some notable differences. It has been described as more mentally and physically oriented than LSD but with a less introspective headspace, accompanied by subtle visuals. It also has a notably shorter duration at around 6 hours and is generally described as less anxiety-provoking than LSD and other lysergamides.  
 
User reports describe the effects of MiPLA as similar to those of LSD, with some marked differences. It is described as being more mentally and physically oriented but with a less introspective headspace and subtle, albeit pronounced visuals. It also has a notably shorter duration at 4-6 hours and is generally described as less anxiety-provoking than other lysergamides. Reports of users taking up to 600ug doses have indicated that higher doses of MiPLA don't change the experience very much if at all, whether visually, mentally, or physically.


Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPLA. It is highly advised to use harm reduction practices when using this substance.
Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPLA. It is highly advised to use harm reduction practices when using this substance.
Line 11: Line 12:
The chemical name of MiPLA is methylisopropyllysergamide. MiPLA belongs to a class of organic compounds known as lysergamides, which are a subclass of ergolines (derivatives of the alkaloids found in the ergot fungus). The most prominent member of the lysergamides is [[LSD]], lysergic acid diethylamide.
The chemical name of MiPLA is methylisopropyllysergamide. MiPLA belongs to a class of organic compounds known as lysergamides, which are a subclass of ergolines (derivatives of the alkaloids found in the ergot fungus). The most prominent member of the lysergamides is [[LSD]], lysergic acid diethylamide.


MiPLA is a structural isomer of LSD. Like LSD, the chemical structure of MiPLA is based on the lysergic acid amide structural skeleton. However, whereas LSD has two ethyl groups bound to the amide nitrogen, MiPLA is substituted with a methyl and isopropyl group.
MiPLA is a structural isomer of LSD. Like LSD, the chemical structure of MiPLA is based on the lysergic acid amide structural skeleton. However, whereas LSD has two ethyl groups bound to the amide nitrogen, MiPLA is substituted with a methyl and isopropyl group. MiPLA is a chiral compound with two stereocenters at R<sub>5</sub> and R<sub>8</sub>. The differences in psychoactivity between the stereoisomers have not yet been investigated.


MiPLA is a chiral compound with two stereocenters at R5 and R8. The differences in psychoactivity between the stereoisomers have not been investigated.
MIPLA and its ethylisopropyl homologue are the only simple N,N-dialkyl lysergamides that approach the potency of LSD itself, being around 1/3-1/2 the potency of LSD,<ref>{{cite journal | vauthors=((Huang, X.)), ((Marona-Lewicka, D.)), ((Pfaff, R. C.)), ((Nichols, D. E.)) | journal=Pharmacology Biochemistry and Behavior | title=Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives | volume=47 | issue=3 | pages=667–673 | date= March 1994 | url=https://linkinghub.elsevier.com/retrieve/pii/0091305794901724 | issn=00913057 | doi=10.1016/0091-3057(94)90172-4}}</ref> while all other dialkyl analogues tested (dimethyl, dipropyl, methylethyl etc.) are only around 1/10 as potent as LSD,<ref>{{cite journal | vauthors=((Hofmann, A.)) | journal=Acta Physiologica Et Pharmacologica Neerlandica | title=Psychotomimetic drugs; chemical and pharmacological aspects | volume=8 | pages=240–258 | date= June 1959 | issn=0001-6748}}</ref> although some N-monoalkyl lysergamides such as the ''sec''-butyl and ''t''-butyl derivatives were also found to show an activity profile and potency comparable to LSD,<ref>{{Citation | vauthors=((Pioch, R. P.)) | title=Lysergic acid amides | url=https://patents.google.com/patent/US2997470A/en}}</ref> and the mono-isopropyl derivative is only slightly weaker than MIPLA. Apart from its lower potency, the hallucinogenic effects of methylisopropyllysergamide are similar to those of LSD itself, and the main use for this drug has been in studies of the binding site at the 5-HT<sub>2A</sub> receptor through which LSD exerts most of its pharmacological effects.<ref>{{cite journal | vauthors=((Nichols, D. E.)) | journal=The Heffter Review of Psychedelic Research. Santa Fe, New Mexico: Heffter Research Institute | title=LSD and its lysergamide cousins | volume=2 | pages=80–87 | date= 2001 | url=http://www.thevespiary.org/rhodium/Rhodium/pdf/nichols/nichols-lsd.lysergamide.cousins.pdf}}</ref>


==Pharmacology==
==Pharmacology==
Owing to similarities in chemical structure, MIPLA and LSD have highly similar binding profiles at monoamine receptors.  
As with its structurally related lysergamides, MiPLA principally acts as a 5-HT2A partial agonist, through which it exerts its psychedelic effects. However, the role of these interactions and how they result in the psychedelic experience is unclear.


One study found MIPLA to fully substitute for LSDin rats, with about half the potency of the training drug
Owing to similarities in chemical structure, MiPLA and LSD have highly similar binding profiles at monoamine receptors (i.e. [[serotonin]], [[dopamine]], and [[norepinephrine]]).{{citation needed}}
 
One study found MiPLA to fully substitute for LSD in rats, with about half the potency of the training drug.{{citation needed}}


==Subjective effects==
==Subjective effects==
Line 29: Line 32:
|{{effects/physical|
|{{effects/physical|


*'''[[Effect::Stimulation]]''' - MiPLA is considered to be primarily stimulating in nature in the same vein as LSD. This is in distinction to other, more commonly used psychedelics such as [[psilocybin]] which are more consistent in producing [[sedation]] and [[muscle relaxation|relaxedness]].
*'''[[Effect::Stimulation]]''' - Similar to LSD, MiPLA is considered to be primarily stimulating in nature. This is in distinction to other, more commonly used psychedelics such as [[psilocybin]] which are more consistent in producing [[sedation]] and [[muscle relaxation|relaxedness]].
*'''[[Effect::Spontaneous bodily sensations]]''' - The "body high" of MiPLA can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It behaves as a euphoric, fast-moving, sharp and location specific tingling sensation. For some, it is manifested spontaneously at different unpredictable points throughout the experience, but for most it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. In comparison to LSD, it is a little less sharp in the tingling sensations it produces as but is otherwise essentially indistinguishable.
*'''[[Effect::Spontaneous bodily sensations]]''' - The "body high" of MiPLA can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It behaves as a pleasurable, fast-moving, sharp and location specific tingling sensation. For some, it is manifested spontaneously at different unpredictable points throughout the experience, but for most it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. In comparison to LSD, MiPLA is a little less sharp in the tingling sensations it produces as but is otherwise essentially indistinguishable.
*'''[[Effect::Physical euphoria]]''' - It should be noted that this effect is not as reliably induceable as it is with substances like [[stimulants]] or [[entactogens]], and can just as easily manifest as physical discomfort without any apparent reason.  
*'''[[Effect::Physical euphoria]]''' - Physical euphoria on MiPLA is not as consistent as it is with substances like [[stimulants]] or [[entactogens]], and can just as easily manifest as physical discomfort without any apparent reason.  
*'''[[Effect::Changes in felt bodily form]]''' - This effect is often accompanied by a sense of warmth or [[Unity and interconnectedness#Unity between the self and specific external systems|unity]] and usually occurs during and up to the peak of the experience or directly afterward. Users can feel as if they are physically part of or conjoined with other objects. This is usually reported as feeling comfortable and peaceful in its sensations.   
*'''[[Effect::Changes in felt bodily form]]''' - This effect is often accompanied by a sense of warmth or [[Unity and interconnectedness#Unity between the self and specific external systems|unity]] and usually occurs during and up to the peak of the experience or directly afterward. Users can feel as if they are physically part of or conjoined with other objects. This is usually reported as feeling comfortable and peaceful in its sensations.   
*'''[[Effect::Tactile enhancement]]''' - Feelings of enhanced tactile sensations are consistently present at moderate levels throughout most MiPLA trips.
*'''[[Effect::Tactile enhancement]]''' - Feelings of enhanced tactile sensations are consistently present at moderate levels throughout most MiPLA trips.
Line 37: Line 40:
*'''[[Effect::Increased bodily temperature]]'''{{citation needed}}
*'''[[Effect::Increased bodily temperature]]'''{{citation needed}}
*'''[[Effect::Nausea]]'''
*'''[[Effect::Nausea]]'''
*'''[[Effect::Stamina enhancement]]''' - This is generally mild in comparison to traditional [[stimulants]].
*'''[[Effect::Stamina enhancement]]''' - Generally mild in comparison to traditional [[stimulants]].
*'''[[Effect::Bodily control enhancement]]'''
*'''[[Effect::Bodily control enhancement]]'''
*'''[[Effect::Appetite suppression]]'''
*'''[[Effect::Appetite suppression]]'''
Line 88: Line 91:
*'''[[Effect::Analysis enhancement]]''' - This effect is consistent in its manifestation and [[outrospection]] dominant.
*'''[[Effect::Analysis enhancement]]''' - This effect is consistent in its manifestation and [[outrospection]] dominant.
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Cognitive euphoria]]''' - This component is, generally speaking less consistent and pronounced than it is with substances like [[psilocybin]] and [[MDMA]]. The mental euphoria experienced on MiPLA is usually simply due to an enhancement of the user’s current psychological and emotional state coupled with its more regularly occurring effect, [[physical euphoria]].
*'''[[Effect::Cognitive euphoria]]'''
*'''[[Effect::Novelty enhancement]]'''
*'''[[Effect::Novelty enhancement]]'''
*'''[[Effect::Immersion enhancement]]'''
*'''[[Effect::Immersion enhancement]]'''
Line 116: Line 119:
}}
}}
{{effects/transpersonal|
{{effects/transpersonal|
Reports indicate that the transpersonal effects of MIPLA are comparatively weaker than those of LSD and other lysergamides, as well as classical psychedelics such as [[psilocybin mushrooms]] or [[mescaline]].  
Reports indicate that the transpersonal effects of MiPLA are comparatively weaker than those of LSD and other lysergamides, as well as classical psychedelics such as [[psilocybin mushrooms]] or [[mescaline]].  


*'''[[Effect::Existential self-realization]]'''
*'''[[Effect::Existential self-realization]]'''
Line 124: Line 127:
}}
}}
===Experience reports===
===Experience reports===
There are currently {{#ask:[[Category:MiPLA]][[Category:Experience]] | format=count}} anecdotal reports which describe the effects of this compound within our [[experience index]].
Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
{{#ask: [[Category:MiPLA]][[Category:Experience]]|format=ul|Columns=1}}
{{#ask: [[Category:MiPLA]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
Additional experience reports can be found here:
* [https://erowid.org/experiences/subs/exp_MIPLA.shtml Erowid Experience Vaults: MiPLA]
 
*[https://erowid.org/experiences/subs/exp_MIPLA.shtml Erowid Experience Vaults: MiPLA]


==Toxicity and harm potential==
==Toxicity and harm potential==
Line 133: Line 137:
The toxicity and long-term health effects of recreational MiPLA use has not been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. This is because MiPLA is a [[research chemical]] with very little history of human usage.  
The toxicity and long-term health effects of recreational MiPLA use has not been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. This is because MiPLA is a [[research chemical]] with very little history of human usage.  


The body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.  
The current body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.  
 
As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute MiPLA exposure. Although no formal studies have been conducted, it is likely that as with [[LSD]] itself, MiPLA is able to be considered non-addictive, with an [[Toxicity::extremely low toxicity]] relative to dose.<ref>Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). [http://www.maps.org/w3pb/new/2008/2008_Passie_23067_1.pdf The Pharmacology of Lysergic Acid Diethylamide: A Review], 14, 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x</ref> It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute MiPLA exposure. 


However, as is the case for LSD, it is possible that MiPLA can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.  
However, as is the case for LSD, it is possible that MiPLA can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.  
Line 142: Line 144:


===Overdose===
===Overdose===
The LD<sub>50</sub> of MiPLA is unknown. Adverse psychological reactions may be more likely to occur at higher doses. Some of these include [[anxiety]], [[delusions]], [[panic attacks]] and more rarely [[seizures]]. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as [[25i-NBOMe]] or [[DOB]]). Administration of [[benzodiazepines]] or [[antipsychotics]] can help to relieve the negative cognitive effects of MiPLA.
The LD<sub>50</sub> of MiPLA is unknown. Adverse psychological reactions may be more likely to occur at higher doses. Some of these include [[anxiety]], [[delusions]], [[panic attacks]] and (more rarely) [[seizures]]. Medical attention is usually only needed in the case of severe psychotic episodes or “fake acid” (a counterfeit substance such as [[25x-NBOMe]] or [[DOx]]). Administration of [[benzodiazepines]] or [[antipsychotics]] can help to relieve the negative psychological effects of MiPLA.


===Dependence and abuse potential===
===Dependence and abuse potential===
Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, MiPLA is [[Addiction potential::not habit-forming]] and that the desire to use it can actually decrease with use.
Like other [[serotonergic psychedelics]], MiPLA is believed to have a [[Addiction potential::low potential for abuse and dependence]]. This is owing to its structural and pharmacological similarities with [[LSD]]. See [[LSD#Dependence and abuse|this section]] to learn more about the dependence and abuse potential of LSD. It should be noted that all claims related to the abuse potential of MiPLA are preliminary and based on anecdotal (as opposed to clinical) evidence and should be interpreted with caution.  


Tolerance to the effects of MiPLA are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). MiPLA presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the use of MiPLA all psychedelics will have a reduced effect.
As with LSD, tolerance to the effects of MiPLA forms [[Time to full tolerance::almost immediately after ingestion]]. After that, it is assumed to take about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be return to baseline (in the absence of further consumption).


Owing to its activity at the 5-HT<sub>2A</sub> receptor, MiPLA presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of MiPLA all psychedelics will have a reduced effect.
Due to its activity at the 5-HT<sub>2A</sub> receptor, MiPLA produces cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of MiPLA all psychedelics will have a reduced effect.


===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
 
{{DangerousInteractions/Psychedelics}}
*'''[[Tramadol]]''' - Tramadol lowers the seizure threshold<ref>Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089</ref> and [[psychedelics]] may act as triggers for seizures, particularly in predisposed individuals.{{citation needed}}
*'''[[Stimulants]]''' - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable [[anxiety]], [[Panic attacks|panic]], [[thought loops]] and [[paranoia]]. This interaction may cause elevated risk of psychosis.{{citation needed}}
*'''[https://en.wikipedia.org/wiki/Lithium_(medication) Lithium]''' - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its [[Glutamate|glutaminergic]] and [[GABA|GABAergic]] effects.{{citation needed}}


==Legal status==
==Legal status==
{{legalStub}}
{{legalStub}}
MiPLA currently exists in a legal grey area in most parts of the world. This means that it is not specifically illegal within most countries but individuals may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.  
MiPLA is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area throughout most of the world, meaning that it might not be specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.  
*'''Austria:''' MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD. {{citation needed}}
 
*'''United States:''' MiPLA is not scheduled but may be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.
*'''Austria''': MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD. {{citation needed}}
*'''Germany''': MiPLA is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref>
*'''Switzerland''': MiPLA can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United States''': MiPLA is not scheduled but may be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.{{citation needed}}


==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
*[[Research chemical]]
*[[Research chemical]]
Line 173: Line 176:


==External links==
==External links==
* [https://en.wikipedia.org/wiki/Methylisopropyllysergamide MiPLA (Wikipedia)]
 
* [https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5327 MiPLA (TiHKAL / Isomer Design)]
*[https://en.wikipedia.org/wiki/Methylisopropyllysergamide MiPLA (Wikipedia)]
*[https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5327 MiPLA (TiHKAL / Isomer Design)]


===Discussion===
===Discussion===
* [http://www.bluelight.org/vb/threads/784440-The-Small-amp-Handy-MIPLA-(Methylisopropyllysergamide)-Thread The Small & Handy MiPLA Thread (Bluelight)]
 
*[http://www.bluelight.org/vb/threads/784440-The-Small-amp-Handy-MiPLA-(Methylisopropyllysergamide)-Thread The Small & Handy MiPLA Thread (Bluelight)]


==Literature==
==Literature==
* Halberstadt, A. L., Klein, L. M., Chatha, M., Valenzuela, L. B., Stratford, A., Wallach, J., ... & Brandt, S. D. (2018). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology, 1-10. http://dx.doi.org/10.1007/s00213-018-5055-9
 
* [https://heffter.org/docs/hrireview/02/chap6.pdf Nichols, D. E. (2001). LSD and its lysergamide cousins. The Heffter Review of Psychedelic Research. Santa Fe, New Mexico: Heffter Research Institute, 80-87.]
*Halberstadt, A. L., Klein, L. M., Chatha, M., Valenzuela, L. B., Stratford, A., Wallach, J., ... & Brandt, S. D. (2018). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology, 1-10. http://dx.doi.org/10.1007/s00213-018-5055-9
*[https://heffter.org/docs/hrireview/02/chap6.pdf Nichols, D. E. (2001). LSD and its lysergamide cousins. The Heffter Review of Psychedelic Research. Santa Fe, New Mexico: Heffter Research Institute, 80-87.]


==References==
==References==
<references />
<references />
[[Category:Substance]]
[[Category:Psychoactive substance]]
[[Category:Hallucinogen]]
[[Category:Psychedelic]]
[[Category:Lysergamide]]
[[Category:Research chemical]]
{{#set:Featured=true}}
Retrieved from "http://psy.st/wiki/MiPLA"